account_id none on file
legal_name Tevogen Inc.
ticker TVGN
cik 1860871
domain tevogen.com
linkedin_company_url https://www.linkedin.com/company/tevogen-bio/
entry_point_account_id none on file
name Tevogen Bio Holdings Inc.
exchange Nasdaq
sector Health Care
sector index/company/sector/health-care/
calls 0 filings 13 executives 7 family 0
why_nownone on file
callsnone on file
filings
of outside consultants, including their fees, stock-based compensation, and related travel expenses; ● costs of laboratory supplies and acquiring materials for preclinical studies and clinical trials; and ● facility-related expenses, which include direct depreciation costs of equipment and expenses for rent and maintenance of facilities and other operating costs.
filing / Aug 14, 2026 / receipt
costs related to the hiring of additional personnel and fees to outside consultants, lawyers, accountants, and recruitment firms, among
filing / Aug 14, 2026 / receipt
of outside consultants, including their fees, stock-based compensation, and related travel expenses; ● costs of laboratory supplies and acquiring materials for preclinical studies and clinical trials; and ● facility-related expenses, which include direct depreciation costs of equipment and expenses for rent and maintenance of facilities and other operating costs.
filing / Aug 14, 2026 / receipt
costs related to the hiring of additional personnel and fees to outside consultants, lawyers, accountants, and recruitment firms, among
filing / Aug 14, 2026 / receipt
stockholder action by written consent may enable more timely responses to corporate matters as they arise, reduce costs borne
filing / Aug 3, 2026 / receipt
of duplicate information received at your household and helps to reduce our expenses. The rule applies to our Notices, annual reports,
filing / Aug 3, 2026 / receipt
Our Board is chaired by Dr. Ryan Saadi and includes Jeffrey Feike, Dr. Keow Lin Goh, Dr. Curtis Patton, Susan Podlogar, and Victor Sordillo as members.
filing / Aug 3, 2026 / receipt
The Board recommends a vote FOR each of Dr. Keow Lin Goh and Victor Sordillo, the Class II director nominees.
filing / Aug 3, 2026 / receipt
Ryan Saadi, our Chief Executive Officer
filing / Aug 3, 2026 / receipt
Kirti Desai, our Chief Financial Officer
filing / Aug 3, 2026 / receipt
Dr. Neal Flomenberg, our Chief Scientific Officer and Global R&D Lead
filing / Aug 3, 2026 / receipt
stockholder action by written consent may enable more timely responses to corporate matters as they arise, reduce costs borne
filing / Aug 3, 2026 / receipt
executives
| Jeff Rogers | Chief Financial Officer | - | receipt |
| Jeffrey Feike | Director | - | receipt |
| Kirti Desai | Chief Financial Officer | receipt | |
| Neal Flomenberg | Chief Scientific Officer and Global R&D Lead | - | receipt |
| Ryan Saadi | Chief Executive Officer | - | receipt |
| Susan Podlogar | Director | - | receipt |
| Victor Sordillo | Director nominee | - | receipt |
familynone on file
upcoming
| 2026-11-13 | earnings call | scheduled | ir |
changes
| 2022-04-15 | Chief Financial Officer, appointed | sec_8k |
mcp_package_hint
slug tevogen-bio-holdings-inc
listing_url https://steadybase.io/company/data/index.json
mcp_url https://mcp.steadybase.io/mcp
steadybase-$